FDA警告勿使用减肥产品吸油基清脂和Bethel 30

圣路易斯(MD Consult)——2013年6月10日，美国食品药品管理局(FDA)针对2种通过互联网和部分零售店促销的减肥产品发布了警告，其商品名分别为“吸油基清脂(Xiyouji Qingzhi)”和“Bethel 30”。FDA对这2种产品进行了分析，发现均含有西布曲明。后者属于管控物质，因安全问题已于2010年10月从美国市场撤市。

使用这些产品可对消费者构成威胁，因为已知西布曲明可显著增加部分患者的血压和(或)脉搏，可给冠状动脉疾病、充血性心力衰竭、心律失常或卒中史患者带来重大风险。西布曲明还可能与消费者服用的其他药物发生相互作用，危及消费者生命。

应将与使用这些产品有关的不良事件报告至FDA的MedWatch不良事件报告系统。

爱思唯尔版权所有  未经授权请勿转载

ST LOUIS (MD Consult) - On June 10, 2013, the US Food and Drug Administration (FDA) issued warnings about 2 products promoted for use in weight loss that are sold via the Internet and in some retail stores. These products are sold under the names Xiyouji Qingzhi and Bethel 30. Both products were analyzed by the FDA and were found to contain sibutramine, a controlled substance that was removed from the US market in October 2010 for safety reasons.

Use of these products pose a threat to consumers because sibutramine is known to substantially increase blood pressure and/or pulse rate in some patients and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This product may also interact, in life-threatening ways, with other medications a consumer may be taking.

Adverse events related to use of these products should be reported to the FDA's MedWatch Adverse Event Reporting Program.

FDA warns against use of weight loss products Xiyouji Qingzhi and Bethel 30.

---------------------------------------------------------------------------------------------------------------------------------------------
欢迎关注Elseviermed官方微信